NEJM Group - Latest News and Information
The episode of AI Grand Rounds features Dr. Kyunghyun Cho, a leading figure in machine translation and protein engineering, discussing how artificial intelligence is expanding into molecular biology. He explains that extracting meaning from text in natural language processing is structurally analogous to decoding physiological function from strings of DNA base pairs, enabling AI‑driven protein function prediction and design. Key insights include Cho’s serendipitous entry into AI during a master’s program in Helsinki, where a random lab assignment led him to implement early neural‑network models. After a stint at the now‑defunct neural‑net group, he moved to Mila (formerly LISA) in Montreal, where collaborations with Yoshua Bengio and Richard Bono merged machine‑translation expertise with drug‑discovery challenges, resulting in novel protein‑modeling pipelines. Memorable anecdotes illustrate the journey: a beer‑talk with Bono that sparked the NLP‑biology analogy, a painfully slow MATLAB matrix‑multiplication loop that taught him the importance of efficient implementation, and a scorching Scottsdale conference where a chance conversation with Bengio secured his post‑doc position. These stories underscore a culture of rapid idea generation—Cho notes that roughly half of their concepts succeeded, far above typical research hit rates. The discussion signals a broader shift: deep‑learning methods are no longer confined to text or vision but are becoming core tools for biomedical research and pharmaceutical innovation. By treating genetic sequences as language, AI can accelerate target identification, streamline protein design, and ultimately shorten drug‑development timelines, highlighting the strategic value of interdisciplinary AI talent and collaborations.
The New England Journal of Medicine’s ADAPT AF‑DES trial examined whether a non‑vitamin K antagonist oral anticoagulant (NOAC) alone could safely replace the conventional dual antithrombotic regimen of NOAC plus clopidogrel in patients with atrial fibrillation who had received a...
The New England Journal of Medicine published a head‑to‑head trial evaluating apixaban (Eliquis) against rivaroxaban (Xarelto) in 2,800 patients with acute pulmonary embolism or deep‑vein thrombosis. The study provides the first direct comparative safety and efficacy data for these two...
The video examines the evolving composition of primary‑care teams, highlighting a shift from an industrial, physician‑centric model toward one that heavily incorporates advanced practice practitioners (APPs) such as nurse practitioners and physician assistants. While policymakers tout team‑based care as the...
Recent discussions in cardiology focus on optimal systolic blood‑pressure targets for hypertension management. The debate pits an intensive goal of less than 120 mm Hg against the more conventional threshold of 140 mm Hg, reflecting evidence from the SPRINT trial and current ACC/AHA guidelines....
NEJM This Week highlighted several pivotal developments. A phase‑3 trial showed finerenone slows kidney disease in type‑1 diabetes patients, while new guidelines recommend early PCI of non‑culprit lesions after STEMI. The episode also introduced an investigational gene‑therapy for Dravet syndrome...
In a recent NOS interview, Lisa Rosenbaum and her panel explored whether online influencers and artificial intelligence could ever replace the trusted, compassionate role of family physicians. They highlighted the allure of digital health advice but stressed the gaps in...
The episode probes a growing tension in primary care between longstanding patient-doctor relationships and emerging tech-driven and influencer-led alternatives. Lisa Rosenbaum and guests argue that while primary care’s human trust and continuity offer distinct benefits, accessibility gaps for roughly 100...
In this NEJM AI Grand Rounds episode, Epic’s senior vice president of research and development, Seth Hain, outlines the company’s strategic approach to artificial intelligence. Central to the discussion is Cosmos, Epic’s de‑identified data repository that now contains over 300 million...
NEJM This Week (Feb 12 2026) highlights several pivotal studies, including promising phase‑III results for novel IgA nephropathy therapies and updated antithrombotic regimens after coronary stenting. Researchers identified the specific antigen driving rare vaccine‑associated clotting syndromes, while a case report underscored the...
